BiotechTube

IC43 + Placebo

Phase 2/3Completed
1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pseudomonas Aeruginosa Infection

Conditions

Pseudomonas Aeruginosa Infection

Trial Timeline

Mar 1, 2012 → Dec 1, 2015

NCT ID
NCT01563263

About IC43 + Placebo

IC43 + Placebo is a phase 2/3 stage product being developed by Valneva SE for Pseudomonas Aeruginosa Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT01563263. Target conditions include Pseudomonas Aeruginosa Infection.

What happened to similar drugs?

1 of 5 similar drugs in Pseudomonas Aeruginosa Infection were approved

Approved (1) Terminated (2) Active (3)
✅TIS or TIPNovartisApproved
🔄tobramycin + tobramycinNovartisPhase 3
🔄Tobramycin inhalation powderNovartisPhase 3
❌AZLI + PlaceboGilead SciencesPhase 3
🔄Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. + Tobramycin inhalation solution using a PARI LC® Plus nebulizer.InsmedPhase 3

Hype Score Breakdown

Clinical
15
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT01563263Phase 2/3Completed
NCT00876252Phase 2Completed
NCT00778388Phase 1Completed

Competing Products

8 competing products in Pseudomonas Aeruginosa Infection

See all competitors
ProductCompanyStageHype Score
AZD0292AstraZenecaPhase 2
42
tobramycin + tobramycinNovartisPhase 3
40
Tobramycin inhalation powderNovartisPhase 3
40
TIS or TIPNovartisApproved
35
AZLI + PlaceboGilead SciencesPhase 3
32
Ciprofloxacin (Cipro, BAYQ3939)BayerPhase 1
26
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. + Tobramycin inhalation solution using a PARI LC® Plus nebulizer.InsmedPhase 3
37
TOBI® PODHALER® + TOBI® + Bethkis® + Cayston®ViatrisPre-clinical
23